One of our missions is to further develop and extend the clinical documentation and therapeutic applications of our Polyvalent Bacterial Mechanical Lysates. Committed to clinical excellence, our Company has teamed up with world-renowned lung and immunology experts to design and conduct our clinical research program. Here is an overview of our current clinical program.
Lallemand Pharma has recently sponsored a multicentre, double-blind, randomized, clinical study involving two hundred eighty eight patients with moderate to very severe COPD : the Advanced Immunological Approach against COPD exacerbations, or AIACE study. This study showed benefits of PMBL® sublingual tablets as add-on therapy by significantly reducing the number of days of hospitalization for COPD patients.
Even though the primary end-point: reduction by 25% of the number of exacerbations was not significant, interesting secondary end-points were positive: reduction of the number of days with fever, reduction of the number of days in poor health, reduction of the number of days of hospitalization.
If you want to read more: AIACE results abstract
Asthma is one of the most common paediatric chronic diseases, affecting up to 30% of children in the Western world. Respiratory tract infections caused either by viruses or bacteria are important factors which may exacerbate the course of the disease in at risk populations. Asthma experts postulated that oral immunostimulation with bacterial lysate, could help controlling the course of asthma and represent an interesting tool for asthma management.
Lallemand Pharma has invested in recent years in clinical research on PMBL® sublingual tablets and its benefits in asthma course and sponsored a randomized clinical trial the EOLIA study (Efficiency Of Lysate In Asthmatic children). The final report of the study is available now .